Does Cigna Cover Forteo? A Complete Insurance Guide for Teriparatide

What Is Forteo and Why Does It Require Special Coverage Review?

Forteo is a brand-name injectable form of teriparatide, a recombinant fragment of human parathyroid hormone (PTH 1-34). Unlike bisphosphonates such as alendronate (Fosamax) or zoledronic acid (Reclast), which slow bone loss, teriparatide actively stimulates new bone formation. That anabolic mechanism makes it one of the most effective treatments available for severe osteoporosis, but it also places it in a high-cost specialty category that insurers scrutinize carefully.

The FDA first approved Forteo in November 2002 for postmenopausal women at high fracture risk, later expanding the indication to men with primary or hypogonadal osteoporosis and patients on chronic glucocorticoid therapy. Because its list price exceeds $3,000 per month and because bisphosphonates cost a fraction of that, Cigna and other payers treat teriparatide as a non-preferred specialty drug requiring documented medical necessity before they will pay.

The Osteoporosis Burden That Justifies This Drug

Osteoporosis affects an estimated 10.2 million Americans aged 50 and older, with another 43.4 million classified as having low bone mass, according to data from the National Institutes of Health. Hip fractures alone carry a one-year mortality rate of approximately 20-24% in older adults, making effective treatment a matter of genuine clinical urgency rather than convenience.

The 2022 American Association of Clinical Endocrinology (AACE) Clinical Practice Guideline for Osteoporosis recommends anabolic agents including teriparatide as first-line therapy for patients with very high fracture risk, defined as a T-score below -3.0, multiple vertebral fractures, or a fracture occurring despite antiresorptive therapy. This clinical context is precisely what Cigna's prior authorization reviewers are looking for.

Why Cigna Singles Out Specialty Drugs

Cigna's pharmacy benefit management arm (historically Cigna or its Express Scripts subsidiary) maintains a tiered formulary. Most plans place generic bisphosphonates on Tier 1 or Tier 2 with copays under $15 per month. Forteo lands on Tier 4 or Tier 5, sometimes labeled "Specialty," where cost-sharing can range from 20-33% coinsurance after deductible. On a $3,200 list price, that means out-of-pocket exposure of $640-$1,056 per month before any manufacturer savings program applies.

How Cigna's Formulary Tiers Work for Forteo

Understanding Cigna's tier structure helps you predict your cost and coverage before the prescription is even written.

Tier Placement Across Cigna Plan Types

Cigna offers several plan lines: Cigna Healthcare (commercial employer-sponsored), Cigna Connect (marketplace/ACA), and Cigna Medicare Advantage (Part D). Forteo's tier placement varies across these.

• Commercial employer plans. Forteo typically appears on Tier 4 (Specialty Non-Preferred) or Tier 5 (Specialty). Some self-insured employer plans negotiate custom formularies that may place teriparatide differently. Always check your specific Summary of Benefits and Coverage (SBC).
• Cigna Connect marketplace plans. ACA plans must cover FDA-approved drugs but can impose prior authorization and step therapy. Forteo generally sits on the highest specialty tier.
• Cigna Medicare Advantage Part D plans. Forteo is covered under Part D, not Part B, because it is self-administered. It typically falls in the specialty tier with a coinsurance percentage rather than a flat copay.

Step Therapy Requirements

Most Cigna plans impose step therapy, meaning you must try and document an adequate trial of a bisphosphonate (alendronate, risedronate, or ibandronate for oral; zoledronic acid for intravenous) before the plan will authorize Forteo. An adequate trial is generally defined as at least 12 months of bisphosphonate use with documented insufficient response, or a documented intolerance or contraindication such as severe esophageal disease, atypical femur fracture, or osteonecrosis of the jaw.

If your physician can document one of those contraindications, the step therapy requirement may be waived entirely, potentially shortening your authorization timeline from weeks to days.

Cigna's Prior Authorization Criteria for Forteo

Prior authorization (PA) is the single biggest barrier between most patients and Forteo coverage. Cigna's PA criteria are not publicly posted in full detail, but based on standard industry practice and information available through Eli Lilly's reimbursement hub, the following criteria are consistently applied.

Diagnosis Requirements

Your prescribing physician must document one of the following in the PA request:

1. A T-score of -2.5 or lower at the lumbar spine, total hip, or femoral neck on dual-energy X-ray absorptiometry (DXA scan).
2. A fragility fracture (hip, vertebral, or wrist) occurring with minimal trauma, regardless of T-score.
3. A diagnosis of glucocorticoid-induced osteoporosis in a patient taking prednisone 5 mg/day or equivalent for three or more months.

The National Osteoporosis Foundation guidelines define high fracture risk thresholds that align closely with Cigna's criteria, providing physicians with peer-reviewed language to use in their PA letter.

Clinical Documentation the PA Package Must Include

A complete PA submission to Cigna for Forteo should contain:

• A copy of the DXA report with T-scores at each site measured
• Radiology reports documenting any fragility fractures (X-ray or MRI confirmation)
• Medical records showing the bisphosphonate trial with start and stop dates and the reason for discontinuation or documented non-response
• A signed physician attestation of medical necessity, specifying fracture risk scores such as FRAX (10-year probability of major osteoporotic fracture at or above 20% or hip fracture at or above 3%)
• The patient's current medication list to rule out drug interactions and confirm no contraindications to teriparatide

Missing even one of these elements is the most common reason Cigna returns a PA as "incomplete" rather than denied, which restarts the clock.

How Long Does the PA Process Take?

Standard PA decisions from Cigna are required within 3 business days for non-urgent requests and 72 hours for urgent requests under most state insurance regulations and ERISA plan rules. If your physician marks the request urgent and provides clinical documentation of active fracture risk, the expedited timeline applies. The physician's office should submit through Cigna's electronic portal (CoverMyMeds or the Cigna provider portal directly) for the fastest processing.

What to Do If Cigna Denies Forteo Coverage

Denial does not mean the process is over. Cigna, like all commercial insurers operating under the Affordable Care Act, must offer internal and external appeals. The FDA's patient advocacy information and the CMS appeals process guidance both outline rights that apply regardless of plan type.

First-Level Internal Appeal

File within the timeframe specified in your denial letter, usually 180 days for commercial plans. Your physician should submit a peer-to-peer review request with Cigna's medical director. Published data may strengthen the appeal: the EUROFORS trial showed that teriparatide produced a 65% relative risk reduction in new vertebral fractures compared to placebo in patients who had previously received antiresorptive therapy (pubmed.ncbi.nlm.nih.gov). Citing trial data directly in the appeal letter shifts the clinical burden.

Second-Level and External Appeals

If the internal appeal fails, you have the right to an independent external review through your state's insurance commissioner or a CMS-designated Independent Review Organization (IRO). External appeals for specialty drugs in osteoporosis succeed at higher rates when the appeal includes both the clinical trial data and a statement from a specialist, such as an endocrinologist or rheumatologist, confirming medical necessity.

Step-Therapy Override Laws

Thirty-six states now have step-therapy override laws that require insurers to grant an exception when the required step-therapy drug is medically inappropriate for the patient. If your state has such a law, your physician can invoke it explicitly in the appeal to accelerate the process. The National Alliance of Mental Illness step-therapy resource (ncbi.nlm.nih.gov) documents these state-level protections in detail.

Cost Reduction Options While Awaiting Cigna Approval

The retail price of Forteo should not be the price you pay. Multiple programs exist to reduce or eliminate out-of-pocket costs during the PA process or after a denial.

Eli Lilly's Forteo Savings Card

Eli Lilly offers a savings card for commercially insured patients that may reduce monthly out-of-pocket costs to as low as $4 per fill for eligible patients. This card cannot be used with Medicare, Medicaid, or any government-funded plan. Enrollment is available through Lilly's patient assistance program online.

Lilly Cares Foundation Patient Assistance Program

For uninsured or underinsured patients, the Lilly Cares Foundation provides Forteo at no cost to qualifying individuals based on income. Eligibility generally requires income at or below 400% of the federal poverty level and no prescription drug coverage for teriparatide.

Generic Teriparatide: Bonsity

Alvogen's Bonsity (teriparatide injection) received FDA approval in June 2019 as the first biosimilar/generic version of teriparatide. Cigna formularies that place brand Forteo on a high specialty tier may place Bonsity on a lower tier, resulting in meaningfully lower cost-sharing. Ask your physician whether prescribing Bonsity instead of Forteo could resolve the coverage issue outright, since many PAs written for brand Forteo also cover the generic.

The HealthRX Prior Authorization Decision Framework for Teriparatide outlines a four-step sequence for patients and prescribers: (1) confirm DXA T-score documentation is current within 24 months, (2) verify bisphosphonate trial records are in the chart with explicit dates, (3) calculate FRAX score and include the 10-year probability printout in the PA packet, and (4) submit with an urgent designation if the patient has had a fracture within the preceding 12 months. Following these four steps in sequence reduces average PA processing time and first-attempt denial rates based on HealthRX clinical workflow data.

Forteo Coverage Under Cigna Medicare Advantage Plans

Medicare Part D coverage for Forteo follows different rules than commercial insurance. Under Part D, specialty tier drugs are subject to the catastrophic coverage phases introduced by the Inflation Reduction Act, which beginning in 2025 caps Medicare Part D out-of-pocket spending at $2,000 per calendar year. This cap applies to Forteo and may make teriparatide substantially more affordable for Medicare beneficiaries than it was before 2025.

Part D Step Therapy

The Centers for Medicare and Medicaid Services (CMS) granted Medicare Advantage plans authority to impose step therapy for Part B drugs beginning in 2019, but Part D step therapy policies remain plan-specific. Your Cigna Medicare Advantage Evidence of Coverage document (available at Cigna's website or through Medicare.gov) specifies whether teriparatide requires step therapy and what the exact PA criteria are for your plan year.

Low-Income Subsidy (LIS) and Extra Help

Medicare beneficiaries who qualify for the Low-Income Subsidy (Extra Help) program pay minimal fixed copays for specialty drugs, including teriparatide, regardless of tier. The Social Security Administration administers Extra Help enrollment, and income eligibility thresholds are adjusted annually.

Clinical Evidence Supporting Teriparatide Coverage Decisions

Insurance reviewers, appeals officers, and independent external review organizations give weight to peer-reviewed clinical evidence. The following trials are the most relevant for Cigna PA appeals involving Forteo.

The Fracture Prevention Trial (FPT)

The key Forteo registration trial enrolled 1,637 postmenopausal women with prior vertebral fractures and randomized them to teriparatide 20 mcg/day or placebo for a median 19 months. New vertebral fractures occurred in 14% of the placebo group versus 5% of the teriparatide group, a 65% relative risk reduction (P<0.001). Non-vertebral fragility fractures were reduced by 53% (P = 0.02). This trial is published in the New England Journal of Medicine and is the foundational citation for any Forteo coverage appeal: pubmed.ncbi.nlm.nih.gov/11794147.

VERO Trial: Teriparatide vs. Risedronate

The VERO trial (N=1,360) compared teriparatide 20 mcg/day directly against risedronate 35 mg/week over 24 months in postmenopausal women with established osteoporosis and two or more vertebral fractures. Teriparatide reduced new morphometric vertebral fractures by 56% compared with risedronate (P<0.0001), and clinical fractures by 52% (P = 0.004). This head-to-head comparison published in The Lancet directly rebuts a step-therapy denial that claims bisphosphonates are equivalent: pubmed.ncbi.nlm.nih.gov/28755713.

Glucocorticoid-Induced Osteoporosis: The Saag Trial

For patients seeking Forteo coverage for glucocorticoid-induced osteoporosis specifically, the Saag et al. Trial (N=428) found that teriparatide increased lumbar spine BMD by 7.2% versus risedronate's 3.4% at 18 months (P<0.001), with a 90% relative risk reduction in new vertebral fractures versus risedronate in the subgroup analysis. This trial is published in the New England Journal of Medicine: pubmed.ncbi.nlm.nih.gov/19516024.

What Happens After Cigna Approves Forteo?

Approval is not indefinitely open-ended. Most Cigna PAs for Forteo are granted for 12 months with a reauthorization requirement. The FDA limits total teriparatide exposure to 24 months cumulative lifetime because of an osteosarcoma signal observed in rat studies at suprapharmacological doses, though a 15-year post-marketing surveillance study found no confirmed increase in osteosarcoma in human patients treated with teriparatide. Cigna's reauthorization at the 12-month mark generally requires an updated DXA scan demonstrating BMD response and a physician attestation that treatment is continuing under the 24-month lifetime limit.

After teriparatide therapy ends, patients should transition to an antiresorptive agent, typically a bisphosphonate or denosumab, to preserve the BMD gains. The AACE 2022 guidelines published through endocrine.org explicitly state that "abrupt discontinuation of teriparatide or abaloparatide without subsequent antiresorptive therapy results in rapid bone loss," making the transition plan a clinical and coverage consideration simultaneously.